May 21, 2015 By Mark Terry and Riley McDermid , BioSpace.com Breaking News Staff Tarrytown, N.Y.-based Regeneron Pharmaceuticals, Inc. announced today that its Phase III trial of sarilumab for rheumatoid arthritis met its co-primary efficacy endpoints. This is just the most recent in a string of successes for Regeneron and its partnership with Paris-based Sanofi .
http://ift.tt/1EZL1qP
No comments:
Post a Comment